ChAd-triCoV/Mac / McMaster University - LARVOL DELTA

AeroVax: A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: McMaster University | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

AeroVax: study protocol for a randomised, double-blind, placebo-controlled, phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans. (PubMed, ERJ Open Res) - "This placebo-controlled phase 2 randomised trial will test the safety and immunogenicity of an inhaled, nebulised ChAd-triCoV/Mac SARS-CoV-2 vaccine that is novel in its administration route and targeting of multiple viral epitopes. The results will provide further information regarding the mucosal T-cell response to immunisation."

Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: McMaster University | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

AeroVax: A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: McMaster University | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

AeroVax: A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: McMaster University | Trial completion date: Jul 2026 ➔ Jan 2027 | Initiation date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: McMaster University | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

AeroVax: A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: McMaster University

New P2 trial • Infectious Disease • Novel Coronavirus Disease

Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: McMaster University | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Dec 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: McMaster University | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4